Alkermes launches phase I in MS with eye on Biogen's Tecfidera
By Michael Fitzhugh
Friday, July 18, 2014
Alkermes plc is ramping up a phase I study of ALKS-8700, a small-molecule prodrug of monomethyl fumarate (MMF) for the treatment of multiple sclerosis.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.